Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Table 1 Baseline clinicopathological characteristics of patients before and after propensity score matching, n (%)
| Variables | Subcategories | All patients (n = 123) | Before PSM | After PSM | ||||
| Control group | Experimental group (n = 31) | P value | Control group | Experimental group (n = 31) | P value | |||
| Age | < 65 | 59 (47.97) | 45 (48.91) | 14 (45.16) | 0.878 | 27 (43.55) | 14 (45.16) | 1.000 |
| ≥ 65 | 64 (52.03) | 47 (51.09) | 17 (54.84) | 35 (56.45) | 17 (54.84) | |||
| Gender | Female | 48 (39.02) | 35 (38.04) | 13 (41.94) | 0.864 | 27 (43.55) | 13 (41.94) | 1.000 |
| Male | 75 (60.98) | 57 (61.96) | 18 (58.06) | 35 (56.45) | 18 (58.06) | |||
| ECOG PS | 0-1 | 80 (65.04) | 59 (64.13) | 21 (67.74) | 0.883 | 41 (66.13) | 21 (67.74) | 1.000 |
| 2 | 43 (34.96) | 33 (35.87) | 10 (32.26) | 21 (33.87) | 10 (32.26) | |||
| Primary tumor location | Right colon | 48 (39.02) | 33 (35.87) | 15 (48.39) | 0.306 | 28 (45.16) | 15 (48.39) | 0.941 |
| Left colon | 75 (60.98) | 59 (64.13) | 16 (51.61) | 34 (54.84) | 16 (51.61) | |||
| Primary tumor surgery | No | 43 (34.96) | 35 (38.04) | 8 (25.81) | 0.309 | 18 (29.03) | 8 (25.81) | 0.935 |
| Yes | 80 (65.04) | 57 (61.96) | 23 (74.19) | 44 (70.97) | 23 (74.19) | |||
| Histological type | Adenocarcinoma | 104 (84.55) | 78 (84.78) | 26 (83.87) | 1.000 | 51 (82.26) | 26 (83.87) | 1.000 |
| Mucinous adenocarcinoma | 19 (15.45) | 14 (15.22) | 5 (16.13) | 11 (17.74) | 5 (16.13) | |||
| Tumor differentiation | Poorly differentiated | 44 (35.77) | 31 (33.70) | 13 (41.94) | 0.541 | 23 (37.10) | 13 (41.94) | 0.821 |
| Moderately to well differentiated | 79 (64.23) | 61 (66.30) | 18 (58.06) | 39 (62.90) | 18 (58.06) | |||
| Lymphovascular perineural invasion | No | 80 (65.04) | 61 (66.30) | 19 (61.29) | 0.773 | 38 (61.29) | 19 (61.29) | 1.000 |
| Yes | 43 (34.96) | 31 (33.70) | 12 (38.71) | 24 (38.71) | 12 (38.71) | |||
| Liver metastasis | No | 51 (41.46) | 39 (42.39) | 12 (38.71) | 0.881 | 21 (33.87) | 12 (38.71) | 0.818 |
| Yes | 72 (58.54) | 53 (57.61) | 19 (61.29) | 41 (66.13) | 19 (61.29) | |||
| Lung metastasis | No | 64 (52.03) | 48 (52.17) | 16 (51.61) | 1.000 | 31 (50.00) | 16 (51.61) | 1.000 |
| Yes | 59 (47.97) | 44 (47.83) | 15 (48.39) | 31 (50.00) | 15 (48.39) | |||
| Number of metastatic organs | 1 | 68 (55.28) | 52 (56.52) | 16 (51.61) | 0.790 | 33 (53.23) | 16 (51.61) | 1.000 |
| ≥ 2 | 55 (44.72) | 40 (43.48) | 15 (48.39) | 29 (46.77) | 15 (48.39) | |||
| RAS | Unknown | 27 (21.95) | 19 (20.65) | 8 (25.81) | 0.816 | 16 (25.81) | 8 (25.81) | 0.943 |
| Wildtype | 44 (35.77) | 33 (35.87) | 11 (35.48) | 20 (32.26) | 11 (35.48) | |||
| Mutation | 52 (42.28) | 40 (43.48) | 12 (38.71) | 26 (41.93) | 12 (38.71) | |||
- Citation: Zhang C, Wu SH, Jin L, Lu L, Li J, Jin S. Propensity score-based real-world study of immune checkpoint inhibitor combination therapy in microsatellite stable/proficient mismatch repair metastatic colorectal cancer. World J Gastrointest Oncol 2026; 18(11): 124022
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/124022.htm
- DOI: https://dx.doi.org/10.4251/wjgo.124022